Novavax secures a non-exclusive licensing deal with Pfizer, validating Matrix-M's platform value and shifting NVAX toward a technology provider model. NVAX receives $30M upfront, a potential $500M in ...
Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. Gordon Scott has been an active investor and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results